-
公开(公告)号：US20100221177A1
公开(公告)日：2010-09-02
申请号：US12389503
申请日：2009-02-20
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
摘要翻译： 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。
-
公开(公告)号：US20100015048A1
公开(公告)日：2010-01-21
申请号：US12553566
申请日：2009-09-03
IPC分类号： A61K51/00 , A61K38/20 , A61K38/21 , A61K39/395 , A61P37/00
CPC分类号： A61K45/06 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K2039/505 , C07K16/2833 , C07K16/2896 , C07K2317/24 , C07K2317/77
摘要： The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
-
公开(公告)号：US07052872B1
公开(公告)日：2006-05-30
申请号：US09382186
申请日：1999-08-23
IPC分类号： A61K39/395 , C07K16/00 , C12P21/04
CPC分类号： A61K51/109 , A61K47/6853 , A61K47/6893 , A61K47/6897 , A61K47/6899 , B82Y5/00 , C07K16/3007 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00
摘要： The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate. The targetable conjugate comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable conjugate further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
摘要翻译： 本发明涉及具有特异性结合目标组织的至少一个臂和特异性结合可靶向缀合物的至少一个其他臂的双特异性抗体或抗体片段。 可靶向缀合物包含载体部分，其包含或携带至少一个可被所述双特异性抗体或抗体片段的至少一个臂识别的表位。 可靶向缀合物还包含一种或多种治疗剂或诊断剂或酶。 本发明提供用于产生双特异性抗体或抗体片段的构建体和方法，以及使用它们的方法。
-
34.发明授权
公开(公告)号：US6090381A
公开(公告)日：2000-07-18
申请号：US20299
申请日：1998-02-06
申请人： Shui-on Leung , Zhengxing Qu
发明人： Shui-on Leung , Zhengxing Qu
IPC分类号： C12N15/09 , A61K38/00 , A61K39/00 , A61K39/395 , A61K47/48 , A61P37/04 , A61P43/00 , C03C17/245 , C03C17/34 , C07K16/28 , C07K16/30 , C07K16/42 , C07K19/00 , C12P21/08 , C23C14/10 , C23C14/34
CPC分类号： A61K47/484 , C07K16/2803 , C07K16/3007 , C07K16/3061 , C07K16/4266 , C23C14/10 , C23C14/3464 , A61K2039/505 , A61K38/00 , A61K39/00 , C07K2317/54 , C07K2319/00
摘要： Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using an antibody that binds with an epitope of an antigen that is associated with a tumor or an infectious agent, and that contains at least one .alpha.-galactosyl epitope. Such an antibody is capable of forming a complex with cells that express the target epitope and with antibodies that bind .alpha.-galactosyl epitopes. Suitable antibodies include molecules that contain at least one engineered glycosylation site in the constant region of the heavy chain.
摘要翻译： 使用与与肿瘤或感染因子相关的抗原表位结合并且含有至少一个α-半乳糖基表位的抗体在哺乳动物中诱导针对肿瘤细胞和感染因子的体液和细胞免疫应答。 这样的抗体能够与表达靶表位的细胞和结合α-半乳糖基表位的抗体形成复合物。 合适的抗体包括在重链的恒定区含有至少一个工程化糖基化位点的分子。
-
公开(公告)号：US08613903B2
公开(公告)日：2013-12-24
申请号：US12556718
申请日：2009-09-10
CPC分类号： C07K16/2833 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/6849 , A61K47/6867 , A61K51/1027 , A61K51/1093 , A61K2039/505 , A61K2039/507 , C07K16/28 , C07K16/2887 , C07K16/4241 , C07K19/00 , C07K2317/24 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92
摘要： Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.
-
36.发明申请Mammalian Cell Lines for Increasing Longevity and Protein Yield from a Cell Culture 有权哺乳动物细胞系从细胞培养增加寿命和蛋白质产量公开(公告)号：US20120196326A1
公开(公告)日：2012-08-02
申请号：US13413871
申请日：2012-03-07
申请人： David M. Goldenberg , Zhengxing Qu , Chien Hsing Chang , Edmund A. Rossi , Jeng-Dar Yang , Diane Nordstrom
发明人： David M. Goldenberg , Zhengxing Qu , Chien Hsing Chang , Edmund A. Rossi , Jeng-Dar Yang , Diane Nordstrom
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/005 , C07K14/4747 , C07K16/00 , C07K16/18 , C07K16/2803 , C07K16/3007 , C07K2317/24 , C07K2317/31 , C12N5/0694 , C12N15/85 , C12N15/86 , C12N2500/90 , C12N2501/48 , C12N2510/02 , C12N2710/20022 , C12N2740/10043 , C12P21/02
摘要： Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.
摘要翻译： 公开了用于增加细胞培养物的寿命并允许增加蛋白质生产的组合物和方法，优选重组蛋白，例如抗体，肽，酶，生长因子，白细胞介素，干扰素，激素和疫苗。 用凋亡抑制基因或载体如三重突变体Bcl-2基因转染的细胞可以在培养物中更长时间地存活，导致蛋白质生物合成的状态和产量的延长。 这样的转染细胞表现出最大的细胞密度，其等于或超过由亲本细胞系实现的最大密度。 转染的细胞也可以预先适应于无血清培养基中生长，大大减少了在无血清培养基中获得蛋白质产生所需的时间。 在某些方法中，预先调节的细胞可以在无血清条件下转化后用于蛋白质生产。 该方法优选涉及真核细胞，更优选哺乳动物细胞。
-
公开(公告)号：US08084583B2
公开(公告)日：2011-12-27
申请号：US12389503
申请日：2009-02-20
IPC分类号： C07K16/00
CPC分类号： A61K45/06 , A61K39/39558 , A61K51/1045 , A61K51/1051 , A61K2039/505 , C07K16/30 , C07K16/3015 , C07K2317/21 , C07K2317/24
摘要： This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.
摘要翻译： 本发明涉及单价和多价单特异性结合蛋白和多价多特异性结合蛋白。 这些结合蛋白的一个实施方案具有一个或多个结合位点，其中每个结合位点与靶抗原或靶抗原上的表位结合。 这些结合蛋白的另一个实施方案具有两个或更多个结合位点，其中每个结合位点对靶抗原上的不同表位具有亲和力，或对靶抗原或半抗原具有亲和力。 本发明还涉及可用于在宿主中表达这些功能性结合蛋白的重组载体。 更具体地，本发明涉及称为RS7的肿瘤相关抗原结合蛋白和其它EGP-1结合蛋白。 本发明还涉及人源化，人和嵌合RS7抗原结合蛋白，以及这种结合蛋白在诊断和治疗中的用途。
-
公开(公告)号：US08084029B2
公开(公告)日：2011-12-27
申请号：US13090391
申请日：2011-04-20
IPC分类号： A61K39/395
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
-
39.发明授权Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof 有权甲胎蛋白Immu31抗体和融合蛋白及其使用方法公开(公告)号：US08017736B2
公开(公告)日：2011-09-13
申请号：US12359745
申请日：2009-01-26
IPC分类号： C12P21/08
CPC分类号： C07K16/30 , A61K41/0095 , A61K47/6843 , A61K49/0002 , A61K51/1018 , A61K2039/505 , C07K16/18 , C07K16/3076 , C07K2317/24 , C07K2317/56 , G01N33/57484 , G01N33/689
摘要： The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.
摘要翻译： 本发明提供人源化，嵌合和人抗甲胎蛋白抗体，融合蛋白及其片段。 抗体，融合蛋白及其片段以及与其它合适抗体的组合可用于治疗和诊断肝细胞癌，肝母细胞瘤，生殖细胞肿瘤癌和其他产生AFP的肿瘤。
-
40.发明授权Mammalian cell lines for increasing longevity and protein yield from cell culture 有权哺乳动物细胞系增加细胞培养的寿命和蛋白质产量公开(公告)号：US07785880B2
公开(公告)日：2010-08-31
申请号：US12405733
申请日：2009-03-17
申请人： David M. Goldenberg , Zhengxing Qu , Chien-Hsing Chang , Edmund A. Rossi , Jeng-Dar Yang , Diane Nordstrom
发明人： David M. Goldenberg , Zhengxing Qu , Chien-Hsing Chang , Edmund A. Rossi , Jeng-Dar Yang , Diane Nordstrom
CPC分类号： C07K16/2896 , A61K2039/505 , C07K14/005 , C07K14/4747 , C07K16/00 , C07K16/18 , C07K16/2803 , C07K16/3007 , C07K2317/24 , C07K2317/31 , C12N5/0694 , C12N15/85 , C12N15/86 , C12N2500/90 , C12N2501/48 , C12N2510/02 , C12N2710/20022 , C12N2740/10043 , C12P21/02
摘要： Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.
摘要翻译： 公开了用于增加细胞培养物的寿命并允许增加蛋白质生产的组合物和方法，优选重组蛋白，例如抗体，肽，酶，生长因子，白细胞介素，干扰素，激素和疫苗。 用凋亡抑制基因或载体如三重突变体Bcl-2基因转染的细胞可以在培养物中更长时间地存活，导致蛋白质生物合成的状态和产量的延长。 这样的转染细胞表现出最大的细胞密度，其等于或超过由亲本细胞系实现的最大密度。 转染的细胞也可以预先适应于无血清培养基中生长，大大减少了在无血清培养基中获得蛋白质产生所需的时间。 在某些方法中，预先调节的细胞可以在无血清条件下转化后用于蛋白质生产。 该方法优选涉及真核细胞，更优选哺乳动物细胞。
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.038 秒)
